Welcome to our dedicated page for Adaptive Biotechnologies SEC filings (Ticker: ADPT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Adaptive Biotechnologies Corporation (ADPT) SEC filings page provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a Nasdaq-listed, commercial-stage biotechnology company, Adaptive Biotechnologies uses these filings to report financial results, material agreements, and other significant corporate events related to its Minimal Residual Disease (MRD) and Immune Medicine businesses.
Among the key documents are current reports on Form 8-K, which the company files to furnish earnings press releases and to describe material events. For example, Adaptive Biotechnologies has filed Form 8-K reports to present quarterly financial results, including segment revenue for its MRD and Immune Medicine businesses, and to disclose the termination of a Strategic Collaboration and License Agreement with Genentech, Inc. related to cancer cell therapy research and development. These filings may also outline expected accounting impacts, such as recognition of remaining non-cash revenue from prior collaboration payments.
In addition to 8-Ks, investors typically look to annual reports on Form 10-K and quarterly reports on Form 10-Q (when available) for more detailed information on revenue composition, operating expenses, segment performance, risk factors, and management’s discussion and analysis. For a company like Adaptive Biotechnologies, these periodic reports help explain how its clonoSEQ MRD business and Immune Medicine programs contribute to overall results, as well as how it manages cash burn targets and investment in research and development.
On this page, Stock Titan pairs real-time updates from the SEC’s EDGAR system with AI-powered summaries that highlight the main points of each filing. Users can quickly see which filings relate to earnings announcements, collaboration changes, or other material events, and can use the underlying documents to analyze ADPT’s financial condition, strategic focus, and progress in MRD and immune medicine initiatives.
Adaptive Biotechnologies Corp Chief People Officer Francis Lo reported an automatic share sale tied to equity compensation. On the RSU vesting date, 38,074 shares of common stock were sold to cover tax withholding obligations under a mandated “sell to cover” arrangement, rather than as a discretionary trade.
After this tax-related sale, Francis Lo directly owned 321,967 common shares. An additional 2,500 common shares were reported as indirectly owned through Lo’s spouse, You Jin Lee.
Adaptive Biotechnologies Corp director Peter M. Neupert reported an acquisition of common stock through a grant or award. On March 4, 2026, he received 15,625 shares at a stated price of $0.0000 per share, bringing his directly owned holdings to 240,315 shares of common stock.
Adaptive Biotechnologies Corp director Robert Hershberg reported an award of common stock. On March 4, 2026, he acquired 15,625 shares of common stock through a grant with a stated price of $0.00 per share. Following this award, his direct holdings total 62,347 shares of common stock.
Adaptive Biotechnologies Corp reported that its Chief People Officer, Francis Lo, acquired 44,063 shares of common stock on March 4, 2026 through a stock grant at no cost, described as a grant, award, or other acquisition. Following this equity award, Lo directly holds 360,041 common shares. The filing also notes an additional 2,500 common shares held indirectly through Lo’s spouse, You Jin Lee.
Adaptive Biotechnologies Corp reported that Chief Commercial Officer, MRD, Susan Bobulsky received two awards of common stock on March 4, 2026. She acquired 59,375 shares in one grant and 62,500 shares in another, both at a reported price of $0.00 per share, increasing her directly held stake.
Adaptive Biotechnologies Corp reported that Chief Commercial Officer, Immune Medicine, Sharon Benzeno acquired 39,063 shares of common stock on March 4, 2026 through a grant or award at a stated price of $0.00 per share. Following this award, Benzeno directly holds 335,854 common shares.
RUBINSTEIN JULIE reported acquisition or exercise transactions in this Form 4 filing.
Adaptive Biotechnologies Corp reported that President and COO Julie Rubinstein received a grant of 81,250 shares of Common Stock on March 4, 2026. The award was recorded at a price of $0.0000 per share, indicating it was granted for no cash consideration. Following this equity grant, Rubinstein’s directly owned holdings increased to 656,485 shares of Common Stock, reflecting a larger personal stake in the company.
Adaptive Biotechnologies Corp reported that Chief Scientific Officer Harlan S. Robins acquired shares of common stock through stock awards. On March 6, 2026, he received 709,220 shares at a price of $0.00 per share, and on March 4, 2026, he received 127,813 shares at $0.00 per share.
These awards relate to performance share units granted on March 6, 2023 for a three-year period ending March 6, 2026. The company certified achievement of the performance goals on March 6, 2026, and the performance share units vested on that date, resulting in common stock delivery.
Adaptive Biotechnologies Corp reported that its Chief Financial Officer, Kyle Piskel, acquired 61,875 shares of common stock as a grant or award on March 4, 2026. The shares were recorded at a price of $0.00 per share, indicating they were not purchased on the open market but received as compensation. Following this transaction, Piskel directly owned 278,512 shares of Adaptive Biotechnologies common stock.
OWEN KATEY EINTERZ reported acquisition or exercise transactions in this Form 4 filing.
Adaptive Biotechnologies Corp director Katey Einterz Owen received an equity award of 15,625 shares of Common Stock on March 4, 2026. The shares were granted at a price of $0.00 per share, indicating a stock award rather than an open‑market purchase. Following this grant, her directly held Common Stock increased to 88,254 shares, reflecting her updated ownership position as a company director.